These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37331095)

  • 1. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
    Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
    Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
    Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
    BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis.
    Charbel A; Tavernar L; Albrecht T; Brinkmann F; Verheij J; Roos E; Vogel MN; Köhler B; Springfeld C; Brobeil A; Schirmacher P; Singer S; Mehrabi A; Roessler S; Goeppert B
    Br J Cancer; 2022 Nov; 127(9):1603-1614. PubMed ID: 36068277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
    Ricci AD; Rizzo A
    Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
    Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
    JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
    Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
    Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
    Kleinegger F; Hofer E; Wodlej C; Golob-Schwarzl N; Birkl-Toeglhofer AM; Stallinger A; Petzold J; Orlova A; Krassnig S; Reihs R; Niedrist T; Mangge H; Park YN; Thalhammer M; Aigelsreiter A; Lax S; Garbers C; Fickert P; Rose-John S; Moriggl R; Rinner B; Haybaeck J
    Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):308-321. PubMed ID: 30419338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.
    Nakagawa H; Hayata Y; Yamada T; Kawamura S; Suzuki N; Koike K
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
    Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Past, Present, and Future Management of Localized Biliary Tract Malignancies.
    Li J; Rocha FG; Mayo SC
    Surg Oncol Clin N Am; 2023 Jan; 32(1):83-99. PubMed ID: 36410923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
    Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
    Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.